Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MC2 25

Drug Profile

MC2 25

Alternative Names: MC2 25 cream; MC2-25; MC2-25 PAD™ Cream; MC2-25 VLS

Latest Information Update: 08 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MC2 Therapeutics
  • Class Antipruritics; Dipeptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pruritus; Vulvar lichen sclerosus

Most Recent Events

  • 02 Feb 2024 MC2 Therapeutics completes the phase-II ITCHINESS clinical trials in Pruritus in Germany, Hungary, Poland, United Kingdom (Topical) (ISRCTN74524864)
  • 07 Dec 2023 MC2 Therapeutics completes enrolment in its phase-II clinical trials in Pruritus in Germany, Hungary, Poland, United Kingdom (Topical) (ISRCTN74524864)
  • 11 Oct 2023 Phase-II clinical trials in Vulval-lichen-sclerosis in Denmark (Topical) (NCT06132919)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top